哌拉西林/三唑巴坦和头孢噻肟治疗呼吸道细菌感染的临床研究

目的：评价哌拉西林／三唑巴坦的有效性和安全性。方法：采用随机对照试验，选择头孢噻肟为对照药物，共治疗呼吸道细菌感染患者60例，哌拉西林／三唑巴坦组和头孢噻肟组各30例，结果：哌拉西林／三唑巴坦组临床治愈率为86．7％（26／30），有效率为93．3％（28／30），细菌清除率为92．9％（26／28），而对照组分别为83．3％（25／30），90％（27／30）和92．3％（24／26），经统计学处理两组差异无显著性，两组不良反应发生率均为3．3％，结论：哌拉西林／三唑巴坦治疗呼吸道细菌的有效和安全性与头噻肟相似，是一种高效，广谱，安全的新型抗菌药。

Clinical study on piperacillin/tazobactam and cefotaxime in treatment of respiratory infections

Objective To evaluate the efficacy and safety of piperacillin/tazobactam. Methods The randomized study was conducted in 60 patients with respiratory tract infections. They were divided into two groups with cefotaxime as control. Results The cure rate, effective rate and bacterial clearance rate for piperacillin/tazobactam were 86.7% (26/30), 93.3%(28/30) and 92.9%(26/28) respectively, and for those of cefotaxime were 83.3% (25/30), 90%(27/30) and 92.3% (34/26), repectively. The rate of adverse reactions for both piperacillin/tazobactam and cefotaxime were 3.3%. Conclusion Piperacillin/tazobactam appeared to be a highly effective and safe agent in treatment of respiratory tract infections and was similar to cefotaxime.